Roche’s Genentech will more than double its initial investment in a biomanufacturing facility in Holly Springs, North Carolina, to approximately $2 billion, bolstering Roche’s and Genentech’s $50-billion investment in US manufacturing and R&D.  

The expansion builds on the company’s May 2025 investment announcement as well as the project’s August 2025 groundbreaking. The expanded investment allows Genentech to build additional production capacity and increase the facility’s output. Set to be operational by 2029, the facility will produce treatments for metabolic conditions, such as obesity. 

Roche and Genentech’s current US footprint includes 13 manufacturing and 15 R&D sites across the company’s pharmaceutical and diagnostics divisions and 25,000 employees in 24 sites across eight US states.  

Source: Genentech